No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OGEN Oragenics
- 1.0864
- -0.0036-0.33%
Trading Apr 24 10:43 ET
4.87MMarket Cap-118P/E (TTM)
1.0950High1.0864Low5.52KVolume1.0950Open1.0900Pre Close6.02KTurnover0.14%Turnover RatioLossP/E (Static)4.48MShares7.740052wk High3.09P/B4.29MFloat Cap1.015052wk Low--Dividend TTM3.95MShs Float59999.9700Historical High--Div YieldTTM0.79%Amplitude1.0150Historical Low1.0890Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Oragenics, Inc. Announces Notification of Noncompliance With Additional NYSE American Continued Listing Standards
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards Download as PDF April 19, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NY
Oragenics, Inc. Files 10K And Provides Company Update
Oragenics, Inc. (the "Company") (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annua
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update Download as PDF April 01, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on dev
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Oragenics Appoints New CMO for Phase II TBI Drug Trial
Oragenics Appoints Kelly As Chief Medical Officer
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg